Hyperbaric Oxygen Therapy for Alzheimer's Disease & Dementia in Concord, CA

Alzheimer's disease is the most common cause of dementia, accounting for 60 to 80% of cases and affecting an estimated 6.7 million Americans over age 65. It is defined by the progressive accumulation of amyloid-beta plaques and tau neurofibrillary tangles in the brain, leading to synaptic dysfunction, neuronal death, and a gradual decline in memory, language, judgment, and the ability to perform daily activities. Vascular dementia — the second most common form — is caused by reduced cerebral blood flow from strokes, small vessel disease, or other cardiovascular events, and frequently co-exists with Alzheimer's pathology in a mixed dementia pattern.

Across Contra Costa County, thousands of families are navigating the profound challenges of caring for a loved one with dementia. The Bay Area's aging population — Contra Costa County's residents over 65 represent one of the fastest-growing segments of the regional population — means that the prevalence and burden of Alzheimer's and related dementias will continue to increase over the coming decade.

While there is currently no cure for Alzheimer's disease, the emerging understanding of its vascular and inflammatory components has opened new therapeutic avenues. The hypoperfusion (reduced blood flow) and neuroinflammation that characterize Alzheimer's are both directly addressable by HBOT, and accumulating clinical evidence supports its use as a meaningful adjunct to standard cognitive care and pharmacological management.

Alzheimer's disease is not purely a protein aggregation disorder — it is increasingly understood as a condition with critical vascular and metabolic components that HBOT is uniquely positioned to address. Cerebral hypoperfusion (reduced blood flow to the brain) precedes clinical symptoms by years in Alzheimer's patients, and the resulting tissue hypoxia accelerates amyloid deposition, tau pathology, and synaptic failure. HBOT directly corrects this hypoxia.

At 1.5 to 2.5 atmospheres of 100% oxygen, HBOT delivers plasma oxygen concentrations sufficient to restore tissue oxygenation even in regions with compromised microvascular perfusion. This triggers multiple beneficial responses: it stimulates angiogenesis (new blood vessel growth) in hypoperfused brain regions, reduces neuroinflammation driven by microglial activation, promotes mitochondrial biogenesis in metabolically failing neurons, and activates stem cell mobilization from bone marrow. Critically, HBOT also upregulates glymphatic function — the brain's waste clearance system — which is responsible for clearing amyloid-beta during sleep and is profoundly impaired in Alzheimer's patients.

A peer-reviewed case series published in the journal Aging documented significant improvements in amyloid PET imaging, cerebral blood flow, and cognitive performance in Alzheimer's patients treated with HBOT. A randomized controlled study from the Sagol Center for Hyperbaric Medicine demonstrated that HBOT produced significant improvements in cognitive function, cerebral blood flow, and quality of life in older adults with significant cognitive impairment. Dr. Toth designs individualized protocols, typically 40 to 60 sessions, and coordinates with patients' neurologists and cognitive care teams throughout the Bay Area to ensure integrated management.